Genomic Landscape of Ceritinib

Stopped early

Conditions studied: Carcinoma, Non-Small-Cell Lung, Non-small Lung Cancer, Non-Small Cell Lung Cancer

In brief

The investigators propose to conduct a retrospective study of single agent ceritinib in patients with previously untreated anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma of the lung with the sole purpose of characterizing the genomic landscape before ceritinib and at the time of disease progression.

Key facts

Study ID

NCT02554591

Run by

Washington University School of Medicine

People needed

6

Starts

2015-09-16

Expected to finish

2018-02-28

Last updated by the study team

2018-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma.
• Presence of known ALK gene rearrangement.
• Consented to HRPO# 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma") with an existing specimen prior to initiation of treatment with ceritinib.
• At least 18 years of age.
• Received treatment with standard of care ceritinib

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.